Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina

Han Kim Ju; Ho Jeong Myung; Ho Yun Kyung; Hun Kim Kye; Koo Kang Dong; Na Hong Seo; Yup Lim Sang; Hyun Lee Sang; Sang Lee Yun; Joon Hong Young; Wook Park Hyung; Weon Kim; Keun Ahn Young; Gwang Cho Jeong; Chun Park Jong; Chaee Kang Jung

doi:10.1253/circj.69.306

Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina

Han Kim Ju, Ho Jeong Myung, Ho Yun Kyung, Hun Kim Kye, Koo Kang Dong, Na Hong Seo, Yup Lim Sang, Hyun Lee Sang, Sang Lee Yun, Joon Hong Young, Wook Park Hyung, Weon Kim, Keun Ahn Young, Gwang Cho Jeong, Chun Park Jong, Chaee Kang Jung

Research output: Contribution to journal › Article

21 Citations (Scopus)

Abstract

Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.

Original language	English
Pages (from-to)	306-310
Number of pages	5
Journal	Circulation Journal
Volume	69
Issue number	3
DOIs	https://doi.org/10.1253/circj.69.306
Publication status	Published - 2005 Mar
Externally published	Yes

Keywords

Angioplasty
Nicorandil
Percutaneous coronary intervention
Unstable angina

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.69.306

Fingerprint Dive into the research topics of 'Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina'. Together they form a unique fingerprint.

Cite this

Ju, H. K., Myung, H. J., Kyung, H. Y., Kye, H. K., Dong, K. K., Seo, N. H., Sang, Y. L., Sang, H. L., Yun, S. L., Young, J. H., Hyung, W. P., Kim, W., Young, K. A., Jeong, G. C., Jong, C. P., & Jung, C. K. (2005). Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circulation Journal, 69(3), 306-310. https://doi.org/10.1253/circj.69.306

Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. / Ju, Han Kim; Myung, Ho Jeong; Kyung, Ho Yun; Kye, Hun Kim; Dong, Koo Kang; Seo, Na Hong; Sang, Yup Lim; Sang, Hyun Lee; Yun, Sang Lee; Young, Joon Hong; Hyung, Wook Park; Kim, Weon; Young, Keun Ahn; Jeong, Gwang Cho; Jong, Chun Park; Jung, Chaee Kang.

In: Circulation Journal, Vol. 69, No. 3, 03.2005, p. 306-310.

Research output: Contribution to journal › Article

Ju, HK, Myung, HJ, Kyung, HY, Kye, HK, Dong, KK, Seo, NH, Sang, YL, Sang, HL, Yun, SL, Young, JH, Hyung, WP, Kim, W, Young, KA, Jeong, GC, Jong, CP & Jung, CK 2005, 'Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina', Circulation Journal, vol. 69, no. 3, pp. 306-310. https://doi.org/10.1253/circj.69.306

Ju, Han Kim ; Myung, Ho Jeong ; Kyung, Ho Yun ; Kye, Hun Kim ; Dong, Koo Kang ; Seo, Na Hong ; Sang, Yup Lim ; Sang, Hyun Lee ; Yun, Sang Lee ; Young, Joon Hong ; Hyung, Wook Park ; Kim, Weon ; Young, Keun Ahn ; Jeong, Gwang Cho ; Jong, Chun Park ; Jung, Chaee Kang. / Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. In: Circulation Journal. 2005 ; Vol. 69, No. 3. pp. 306-310.

@article{e44ef5e888e04d1ab6a45c7102985362,

title = "Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina",

abstract = "Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.",

keywords = "Angioplasty, Nicorandil, Percutaneous coronary intervention, Unstable angina",

author = "Ju, {Han Kim} and Myung, {Ho Jeong} and Kyung, {Ho Yun} and Kye, {Hun Kim} and Dong, {Koo Kang} and Seo, {Na Hong} and Sang, {Yup Lim} and Sang, {Hyun Lee} and Yun, {Sang Lee} and Young, {Joon Hong} and Hyung, {Wook Park} and Weon Kim and Young, {Keun Ahn} and Jeong, {Gwang Cho} and Jong, {Chun Park} and Jung, {Chaee Kang}",

year = "2005",

month = mar,

doi = "10.1253/circj.69.306",

language = "English",

volume = "69",

pages = "306--310",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "3",

}

TY - JOUR

T1 - Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina

AU - Ju, Han Kim

AU - Myung, Ho Jeong

AU - Kyung, Ho Yun

AU - Kye, Hun Kim

AU - Dong, Koo Kang

AU - Seo, Na Hong

AU - Sang, Yup Lim

AU - Sang, Hyun Lee

AU - Yun, Sang Lee

AU - Young, Joon Hong

AU - Hyung, Wook Park

AU - Kim, Weon

AU - Young, Keun Ahn

AU - Jeong, Gwang Cho

AU - Jong, Chun Park

AU - Jung, Chaee Kang

PY - 2005/3

Y1 - 2005/3

N2 - Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.

AB - Background: The purpose of the study was to prospectively evaluate the protective effect of nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UAP). Methods and Results: Two hundred patients (61±10 year-old, male 143) diagnosed with UAP at an emergency medical center were randomly assigned to 2 groups: intravenous isosorbide dinitrate, Group I (n=100), or intravenous nicorandil, Group II (n=100). PCI was performed 12-48h after infusion of each agent. Serum concentrations of creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), and I (cTnI) were measured before and 6, 12, 24h after PCI. Patients with non-coronary chest pain, requiring emergency coronary angiogram, temporary pacemaker or glycoprotein IIb/IIIa receptor blocker were excluded. PCI was successfully performed in 96 patients (Group I=54, 61.7±8.2 years, 32 males; Group 11=42, 60.4±11.7 years, 27 males). No significant differences in clinical or coronary angiographic characteristics were observed between the 2 groups. The concentration of CK-MB was elevated in 9 patients (17%) of Group I and 6 (14%) of Group II, cTnT in 16 (30%), 6 (14%) and cTnI in 25 (46%), 9 (21%) after PCI. Elevation of any troponin was less frequent in Group II [28/54 (52%) vs 10/42 (24%) patients, p=0.01]. Major adverse coronary events during the 6-month clinical follow-up occurred in 9 (17%) of Group I and 5 patients of Group II (12%, p=NS). Follow-up echocardiography revealed lower left ventricular ejection fraction in Group I than in Group II (65.4±7.2% vs 71.0±6.7%, p=0.03). Conclusion: Nicorandil has a myocardial protective effect during PCI in patients with UAP.

KW - Angioplasty

KW - Nicorandil

KW - Percutaneous coronary intervention

KW - Unstable angina

UR - http://www.scopus.com/inward/record.url?scp=20144377820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144377820&partnerID=8YFLogxK

U2 - 10.1253/circj.69.306

DO - 10.1253/circj.69.306

M3 - Article

C2 - 15731536

AN - SCOPUS:20144377820

VL - 69

SP - 306

EP - 310

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 3

ER -